Physicians' Academy for Cardiovascular Education
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
In this e-learning program, three experts discuss outcomes of relevant trials and guidelines that provide evidence and recommendations for using SGLT2i to improve outcomes in patients with CKD.
EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite endpoint of time to first event of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.
ESC HF 2021 Dapagliflozin improved HF symptoms (measured by KCCQ-TSS) in HFrEF compared to placebo, but did not improve physical limitations (measured by KCCQ-PLS) or 6 minute walk distance. No significant improvements with dapagliflozin in any of these outcomes were seen in HFpEF.
ESC HF 2021 Use of empagliflozin was associated with reduced risk of CV and renal events, and all-cause mortality compared to use of DPP-4i in T2DM patients in a real world setting.
ESC HF 2021 Key messages of the 2021 ESC/HFA Guidelines for Heart Failure include a simplified treatment algorithm for HFrEF based on early administration of 4 classes of drugs, including SGLT2i, and tailored-treatment approaches based on phenotypes.
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.
The European Commission has extended the indication for empagliflozin: empagliflozin is now also approved for the treatment of adults with HFrEF.
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.
ERA-EDTA 2021 Prof. Wanner presents the results of a post hoc analysis of EMPA-REG OUTCOME, in which potential mediators of the treatment effect of empagliflozin on kidney outcomes were explored.
The Heart Failure Association of the European Society of Cardiology has published a consensus document with patient profiles that may be relevant for treatment implementation in HFrEF patients.
Following the results from the EMPEROR-Reduced trial, the CHMP has issued a recommendation for empagliflozin in patients with symptomatic chronic HFrEF with or without T2DM to reduce the combined risk of CV death or HF hospitalization.
